Skip to content
10-Q

Quarterly Report

EVOFEM BIOSCIENCES, INC. EVFM

0001493152-26-023928

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 132.53M sh
Shares Diluted Q1 2026 · Mar 31, 2026 133.25M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 6.16B sh
Capex Q1 2026 · Mar 31, 2026 $2K
Operating Cash Flow Q1 2026 · Mar 31, 2026 $2.3M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $560K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $1.49M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$77.63M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$74.34M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$69.59M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$71.26M
Current Liabilities Q1 2026 · Mar 31, 2026 $78.75M
Current Liabilities Q1 2026 · Dec 31, 2025 $84.82M
Total Liabilities Q1 2026 · Mar 31, 2026 $80.15M
Total Liabilities Q1 2026 · Dec 31, 2025 $89.71M
Current Assets Q1 2026 · Mar 31, 2026 $6.06M
Current Assets Q1 2026 · Dec 31, 2025 $15.28M
Total Assets Q1 2026 · Mar 31, 2026 $7.44M
Total Assets Q1 2026 · Dec 31, 2025 $20.27M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.04
Eps Diluted Q1 2026 · Mar 31, 2025 $0.00
Eps Basic Q1 2026 · Mar 31, 2026 −$0.04
Eps Basic Q1 2026 · Mar 31, 2025 $0.01
Sga Expense Q1 2026 · Mar 31, 2026 $2.37M
Sga Expense Q1 2026 · Mar 31, 2025 $2.37M
Net Income Q1 2026 · Mar 31, 2026 −$5.47M
Net Income Q1 2026 · Mar 31, 2025 $956K
Operating Income Q1 2026 · Mar 31, 2026 −$4.57M
Operating Income Q1 2026 · Mar 31, 2025 $327K
Cost Of Revenue Q1 2026 · Mar 31, 2026 $410K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $365K
Revenue Q1 2026 · Mar 31, 2026 $899K
Revenue Q1 2026 · Mar 31, 2025 $845K
Short Term Debt Q1 2026 · Dec 31, 2025 $147K